Insider Selling: Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Sells $300,000.00 in Stock

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Kim D. Blickenstaff sold 10,000 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the director now owns 195,190 shares in the company, valued at approximately $5,855,700. The trade was a 4.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tandem Diabetes Care Stock Up 0.2 %

TNDM stock opened at $30.81 on Monday. Tandem Diabetes Care, Inc. has a one year low of $18.45 and a one year high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The firm has a 50-day simple moving average of $36.16 and a two-hundred day simple moving average of $41.24.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $243.97 million during the quarter, compared to analysts’ expectations of $224.14 million. During the same quarter in the prior year, the company posted ($0.38) earnings per share. Tandem Diabetes Care’s revenue for the quarter was up 31.4% compared to the same quarter last year. As a group, research analysts forecast that Tandem Diabetes Care, Inc. will post -1.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TNDM shares. Canaccord Genuity Group began coverage on shares of Tandem Diabetes Care in a report on Thursday, August 8th. They issued a “buy” rating and a $57.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Tandem Diabetes Care in a research report on Friday, October 4th. They set a “neutral” rating and a $46.00 target price on the stock. Sanford C. Bernstein started coverage on Tandem Diabetes Care in a report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price target for the company. Royal Bank of Canada initiated coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price objective on the stock. Finally, UBS Group upgraded Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $54.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brooklyn Investment Group acquired a new stake in Tandem Diabetes Care in the third quarter worth about $28,000. Assetmark Inc. acquired a new stake in Tandem Diabetes Care in the 3rd quarter worth approximately $29,000. ORG Wealth Partners LLC purchased a new stake in Tandem Diabetes Care during the 3rd quarter worth approximately $30,000. ORG Partners LLC purchased a new stake in Tandem Diabetes Care during the 2nd quarter worth approximately $31,000. Finally, Waldron Private Wealth LLC acquired a new position in Tandem Diabetes Care during the 3rd quarter valued at approximately $50,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.